Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Relacorilant once daily · 1 trial · 4 indications
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab | EXPERIMENTAL | In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
| Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab | EXPERIMENTAL | In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
| Arm C: Relacorilant in Combination with Nab-Paclitaxel | EXPERIMENTAL | In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
| Name | Type | Description |
|---|---|---|
| Relacorilant 150 mg once daily (QD) | DRUG | Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion. |
| Nab-paclitaxel 80 mg/m^2 | DRUG | Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
| Bevacizumab 10 mg/kg | DRUG | Bevacizumab is administered as IV infusion on Days 1 and 15. |
Inclusion Criteria: Arms A and B * Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma * Arm A Only: Platinum-resistant disease * Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) i...
Top 20 of 58 competitors
Relacorilant once daily is an investigational small molecule being studied for the treatment of ovarian cancer. It is currently in Phase 2 clinical development as a combination therapy for gynecological cancers, including ovarian cancer. The drug is not yet approved and remains under investigation in clinical trials.
Relacorilant once daily targets the NR3C1 receptor, also known as the glucocorticoid receptor. It acts as an antagonist of this receptor, meaning it blocks its activity. This mechanism is being explored in the context of ovarian cancer treatment, where the drug is combined with other regimens.
Relacorilant once daily is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company traded on the Nasdaq under the ticker symbol CORT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with gynecological cancers.
Relacorilant once daily is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being evaluated in an active Phase 2 trial for the treatment of ovarian cancer and other gynecological cancers.
Relacorilant once daily is being studied in a single active Phase 2 clinical trial with the identifier NCT06906341. This trial, titled 'Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers,' is recruiting patients with ovarian cancer, fallopian tube cancer, peritoneal neoplasms, and endometrial cancer. The trial is enrolling 270 female participants aged 18 years and older across multiple countries.
Yes, Relacorilant once daily is also known as Relacorilant 150 mg once daily (QD). The drug is being developed under this alternative name, which specifies the once-daily dosing regimen at a 150 mg dose. Both names refer to the same investigational drug being studied in ovarian cancer.